Literature DB >> 24331369

Aspirin reduces lung cancer metastasis to regional lymph nodes.

Fumihiro Ogawa1, Hideki Amano2, Yoshiya Ito2, Yoshio Matsui3, Kanako Hosono2, Hidero Kitasato4, Yukitoshi Satoh3, Masataka Majima5.   

Abstract

BACKGROUND: Lung cancer is the main cause of cancer-related death worldwide. The high mortality is probably attributable to early metastasis; however, the mechanism underlying metastasis to regional lymph nodes is still unknown. Cyclooxygenase (COX)-derived prostaglandin E2 (PGE2) induces tumor growth and metastasis and is associated with a poor prognosis. The present study investigated the effect of an authentic COX inhibitor, aspirin, on regional lymph node metastasis during the development of lung cancer in mice.
METHODS: An orthotopic intrapulmonary implantation model based on male C57BL/6 (6-8-weeks-old) mice was used. The lungs were injected with a solution containing Lewis lung carcinoma (LLC) cells overexpressing green fluorescent protein (GFP) and BD Matrigel(®). The effect of aspirin on mediastinal lymph node metastasis of LCC cells from the primary injection sites was then examined.
RESULTS: The implantation process took approximately 30 s per mouse and operative mortality was 10%. Single pulmonary nodules developed at the implanted site in 95% of animals, and regional mediastinal lymph node metastasis was observed at 14 days post-LLC-GFP cell injection in all mice that formed a primary lung tumor. The mean survival time of mice injected with LLC-GFP cells was 15±3 days (range, 12-22 days). Histopathological analysis revealed that no metastatic tumors developed in the regional mediastinal lymph nodes by Day 10-12 post-LLC-GFP cell injection and no metastasis to distant organs or distant lymph nodes was observed by Day 21 post-injection. Oral administration of aspirin (100 mg/kg, twice a day) after LLC-GFP cell injection inhibited metastasis to the regional lymph nodes, with no significant suppression of primary tumor growth in the lungs. Aspirin treatment led to a significant reduction in mortality (P<0.0001).
CONCLUSIONS: The present lymph node metastasis model is useful for evaluating the efficacy of agents that inhibit tumor metastasis to the regional lymph nodes. Aspirin reduced the metastasis of LLC-GFP cells injection to the regional lymph nodes, with a significant reduction in mortality. These findings suggested that COX inhibitors have potential for preventing lymph node metastasis.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Aspirin; Lung cancer; Lymph node metastasis

Mesh:

Substances:

Year:  2013        PMID: 24331369     DOI: 10.1016/j.biopha.2013.11.006

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  8 in total

1.  Racial and Ethnic Differences in the Relationship between Aspirin Use and Non-Small Cell Lung Cancer Risk and Survival.

Authors:  Patricia Erickson; Lisa D Gardner; Christopher A Loffredo; Diane Marie St George; Elise D Bowman; Janaki Deepak; Khadijah Mitchell; Claire L Meaney; Patricia Langenberg; Debra H Bernat; Sania Amr; Bríd M Ryan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-08-31       Impact factor: 4.254

2.  Antiplatelet agents for cancer treatment: a real perspective or just an echo from the past?

Authors:  Marek Z Wojtukiewicz; Dominika Hempel; Ewa Sierko; Stephanie C Tucker; Kenneth V Honn
Journal:  Cancer Metastasis Rev       Date:  2017-06       Impact factor: 9.264

3.  Effects of chronic low-dose aspirin treatment on tumor prevention in three mouse models of intestinal tumorigenesis.

Authors:  Nadine Rohwer; Anja A Kühl; Annika I Ostermann; Nicole Marie Hartung; Nils Helge Schebb; Dieter Zopf; Fiona M McDonald; Karsten-H Weylandt
Journal:  Cancer Med       Date:  2020-01-29       Impact factor: 4.452

4.  Unexpected effects of long-term treatment with acetylsalicylic acid on late phase of pulmonary metastasis in murine model of orthotopic breast cancer.

Authors:  Marta Smeda; Agnieszka Kij; Bartosz Proniewski; Karolina Matyjaszczyk-Gwarda; Kamil Przyborowski; Agnieszka Jasztal; Katarzyna Derszniak; Piotr Berkowicz; Anna Kieronska-Rudek; Marta Stojak; Magdalena Sternak; Stefan Chlopicki
Journal:  PLoS One       Date:  2020-04-06       Impact factor: 3.240

5.  Phosphodiesterase 4A confers resistance to PGE2-mediated suppression in CD25+ /CD54+ NK cells.

Authors:  Ziqing Chen; Ying Yang; Shi Y Neo; Hao Shi; Yi Chen; Arnika K Wagner; Karin Larsson; Le Tong; Per-Johan Jakobsson; Evren Alici; Jing Wu; Yihai Cao; Kai Wang; Lisa L Liu; Yumeng Mao; Dhifaf Sarhan; Andreas Lundqvist
Journal:  EMBO Rep       Date:  2021-01-22       Impact factor: 8.807

6.  The association of aspirin use with overall survival of patients with inoperable non-small cell lung cancer: a retrospective study.

Authors:  Min-Chun Chuang; Yao-Hsu Yang; Meng-Jer Hsieh; Yu-Ching Lin; Tsung-Ming Yang; Pau-Chung Chen; Ming-Szu Hung
Journal:  BMC Cancer       Date:  2021-11-22       Impact factor: 4.430

7.  Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer.

Authors:  Xiaoke Liu; Lingzhi Hong; Monique Nilsson; Shawna Marie Hubert; Shuhong Wu; Waree Rinsurongkawong; Jeffery Lewis; Amy Spelman; Jack Roth; Steven Swisher; Yong He; J Jack Lee; Bingliang Fang; John V Heymach; Jianjun Zhang; Xiuning Le
Journal:  Lung Cancer       Date:  2020-09-09       Impact factor: 5.705

8.  Low-dose aspirin and survival from lung cancer: a population-based cohort study.

Authors:  Úna C Mc Menamin; Chris R Cardwell; Carmel M Hughes; Liam M Murray
Journal:  BMC Cancer       Date:  2015-11-17       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.